Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CTSL1
REST API REST API
Homo sapiens
CTSL1 is differentially expressed in 293 experiments: 119 organism parts: placenta, cerebellum, ... (117 more);, 195 disease states: normal, glioblastoma, ... (193 more);, 108 cell types 459 cell lines 39 compound treatments and 76 other conditions.
Synonyms FLJ31037, CTSL
Orthologs F1NYJ1_CHICK (Gallus gallus)   BX000534.3 (Danio rerio)   ctsl1b (Danio rerio)   CABZ01044814.2 (Danio rerio)   BX322603.1 (Danio rerio)   ctsll (Danio rerio)   BX465840.1 (Danio rerio)   wu:fa26c03 (Danio rerio)   ctsl1a (Danio rerio)   zgc:174154 (Danio rerio)   zgc:174153 (Danio rerio)   Cp1 (Drosophila melanogaster)   BX000534.6 (Danio rerio)   wu:fb37b09 (Danio rerio)   ctsl2 (Xenopus laevis)   zgc:174855 (Danio rerio)   BX322603.2 (Danio rerio)   (Compare orthologs)
InterPro Term Peptidase_C1A_C, Prot_inhib_I29
Gene Ontology Term protein binding, histone binding, lysosome, peptidase activity, extracellular region, cysteine-type endopeptidase activity, nucleus, proteolysis, cysteine-type peptidase activity, macrophage apoptosis
UniProt Accession P07711, Q9HBQ7, Q5T8F0, Q8NG13, Q5K630
Search EB-eye ENSG00000135047
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-22541, E-GEOD-6573, E-GEOD-1577, E-GEOD-7540, ... (27 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, ... (45 experiments)

Factor Value U/D Experiments
K562
3
E-GEOD-96, E-GEOD-24147, E-MTAB-37
MCF-7
3
E-GEOD-19639, E-GEOD-3529, E-GEOD-20081
LNCaP
2
E-GEOD-14464, E-GEOD-14990
A549
2
E-GEOD-3202, E-GEOD-6013
AGS
2
E-GEOD-15460, E-MTAB-37
H1437
2
E-GEOD-16194, E-MTAB-62
453 more value(s).


Cell type

studied in E-GEOD-492, E-GEOD-20193, E-MEXP-750, E-GEOD-20677, E-TABM-34, ... (57 experiments)

Factor Value U/D Experiments
whole blood
2
E-GEOD-3026, E-MTAB-25
spheroid recovery
1
E-GEOD-4219
multipotent adult progenitor cell
1
E-MEXP-466
PBMCs
1
E-GEOD-20677
mononuclear cell
1
E-GEOD-7307
vascular smooth muscle cell
1
E-TABM-130
102 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-1577, E-MTAB-680, E-MTAB-62, E-GEOD-5418, ... (53 experiments)

Factor Value U/D Experiments
acute promyelocytic leukemia
4
E-GEOD-96, E-MTAB-62, E-GEOD-1729, E-GEOD-995
cervical carcinoma
2
E-MTAB-62, E-MTAB-37
choriocarcinoma
2
E-MTAB-37, E-MTAB-62
chronic lymphocytic leukemia
2
E-MTAB-37, E-GEOD-6691
lung adenocarcinoma
2
E-MTAB-37, E-MTAB-62
melanoma
2
E-MTAB-62, E-MTAB-37
189 more value(s).


Compound treatment

studied in E-GEOD-5741, E-GEOD-5542, E-TABM-782, E-GEOD-5824, E-GEOD-3140, ... (27 experiments)

Factor Value U/D Experiments
none
2
9
E-GEOD-5542, E-GEOD-5099, E-GEOD-5741, E-MEXP-1601, E-GEOD-412, ... (11 experiments)
control
3
E-GEOD-4006, E-GEOD-3284, E-GEOD-5339
bis [(+)-tartrato] diantimonate (III) dipotassium trihydrate
1
E-GEOD-6907
17beta-estradiol
4
1
E-GEOD-4006
keratinocyte growth factor
1
E-GEOD-7216
CNOT7+CNOT8
1
E-MEXP-2218
33 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
tunicamycin
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37, E-GEOD-14359

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-MEXP-1251, ... (9 experiments)

Clinical treatment
studied in E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-1614, E-GEOD-20033, E-MEXP-2359, E-GEOD-2666, E-MTAB-62 ... (5 experiments)

Disease staging
studied in E-GEOD-89, E-GEOD-1323, E-GEOD-22541, E-GEOD-2509, E-TABM-147, ... (6 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-1643

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-7011, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, E-GEOD-6431, ... (6 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-3494, E-GEOD-17476, E-GEOD-21750, E-TABM-321, ... (11 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-6432, E-GEOD-5681, E-GEOD-12773, E-TABM-127, ... (12 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-TABM-740, E-GEOD-1926, E-MEXP-2069, ... (29 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-MEXP-561, E-GEOD-360 ... (5 experiments)

Initial distant metastases
studied in E-GEOD-22541

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-22056

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Localisation of metastases
studied in E-GEOD-22541

Lymph node status
studied in E-GEOD-6532

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801

Organism status
studied in E-GEOD-19188

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, E-GEOD-4600, E-GEOD-7114, ... (6 experiments)

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, ... (6 experiments)

Replicate
studied in E-GEOD-10896

RNAi
studied in E-MEXP-2115, E-GEOD-1703, E-GEOD-12438, E-GEOD-1676, E-GEOD-3697, ... (7 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-18995

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-1643, E-GEOD-19069, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-20114, E-GEOD-11886

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-21909, E-GEOD-19246, E-GEOD-19136, E-GEOD-13818, E-GEOD-15799, ... (6 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-3494, E-GEOD-22541, E-GEOD-1561, ... (8 experiments)

Tumor size
studied in E-GEOD-8167

Vehicle
studied in E-GEOD-5258

Processing time: 0.386 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM